Mounjaro side effects: A complete, evidence-based guide for UK patients

What is Mounjaro (Tirzepatide) and why is it prescribed in the UK?

Mounjaro contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual-action mechanism distinguishes it from single GLP-1 agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza).

In the UK, Mounjaro is currently approved for:

• Type 2 diabetes mellitus: As an add-on to diet and exercise, with or without other anti-diabetic medicines, to improve blood sugar control.
• Weight management (obesity/overweight): In adults with a BMI over 30 kg/m², or over 27 kg/m² with at least one weight-related health condition such as hypertension, dyslipidaemia, or obstructive sleep apnoea.

Mounjaro is available via private prescription from registered clinics, or through NHS specialist tier 3/4 weight management services, though it is not yet routinely available via standard NHS GP prescription for weight loss.

Mounjaro is self-injected once weekly, starting at 2.5 mg and increasing every four weeks to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg as tolerated. This dosing schedule is central to understanding when and why side effects occur.

Mounjaro side effects by frequency: Official MHRA Categories

The MHRA patient information leaflet categorises side effects as follows:

Source: Mounjaro (tirzepatide) Summary of Product Characteristics (SmPC), Eli Lilly and Company Ltd, as approved by the MHRA. Always refer to the current Patient Information Leaflet (PIL) at medicines.org.uk for the most up-to-date information.

Gastrointestinal side effects: What causes them and how long do they last?

GLP-1 and GIP hormones naturally slow gastric emptying, the rate at which food moves from the stomach into the small intestine. This is part of what makes you feel fuller for longer, but it also means food can sit in the stomach longer than usual, triggering nausea, indigestion, and a heavy sensation after meals.

Nausea

Nausea is the most commonly reported side effect, affecting more than 1 in 10 people. It is most pronounced on the day of or after your injection, during the first 2–4 weeks at any new dose, and after large, fatty, or spicy meals. In the SURMOUNT-1 trial, nausea was reported in approximately 24–33% of participants across the 5–15 mg dose groups, with most episodes mild to moderate. It typically resolves within 4–8 weeks of stabilising on a dose.

Vomiting

Vomiting is more common with Mounjaro than with Wegovy at comparable doses. It follows the same pattern as nausea, peaking at dose initiation or increases, and usually reduces as the body adjusts. If vomiting is persistent or causes dehydration, contact your prescriber. It may be advisable to delay the next dose increase or temporarily reduce the dose.

Diarrhoea and Constipation

Diarrhoea is more common in the early titration phase; whereas constipation tends to emerge at higher doses. Staying well hydrated (1.5–2 litres daily), maintaining adequate fibre intake, and keeping active can help manage both.

Indigestion, Burping, and Stomach Pain After Eating

Indigestion and excessive burping are very commonly reported, more so than with semaglutide, and are directly linked to delayed gastric emptying. Stomach discomfort after eating is classified as common. To minimise this you can:

• Eat smaller, more frequent meals rather than three large ones.
• Chew food slowly and thoroughly.
• Avoid lying down for at least 2 hours after eating.
• Reduce carbonated drinks, which worsen bloating and burping.
• Eat low-fat, easily digestible foods, especially in the first weeks at each new dose.

Injection-site reactions: What to expect and how to prevent them

Injection-site reactions (redness, swelling, bruising, or mild pain) are classified as very common but are usually mild and resolve within a few days. Severe or persistent reactions should be reported to your prescriber and via the MHRA Yellow Card scheme.

Practical injection tips

• Rotate sites every week. The abdomen, outer thigh, and upper arm are all suitable.
• Pinch the skin lightly before injecting if you have less subcutaneous fat.
• Allow the pen to reach room temperature (15–30 minutes out of the fridge). Cold injections are more uncomfortable.
• Keep the pen pressed against the skin for at least 10 seconds after the click to ensure full dose delivery.
• Do not rub the injection site afterwards, as this can increase local irritation.
• Avoid areas of hardened tissue, scars, bruises, or broken skin.

Hair loss, "Mounjaro face", and other appearance-related changes

Alongside the previously discussed gastrointestinal side effects, some people on Mounjaro notice changes to their appearance as weight loss progresses. Most of these are a consequence of losing weight rapidly rather than a direct effect of the medication itself, and the majority resolve with time.

Hair Loss (Alopecia / Telogen Effluvium)

Hair loss is classified as common (1–10 in 100 people). In most cases, it is not a direct effect of tirzepatide but a physiological response to rapid weight loss known as telogen effluvium, where metabolic stress causes hair follicles to shift into the resting phase, leading to increased shedding typically 2–4 months after the trigger.

• Shedding is usually diffuse rather than patchy.
• It typically peaks at 3–6 months and resolves within 6–12 months as weight loss slows.
• Adequate protein intake (1.2–1.6 g per kg of body weight daily) is the most important dietary intervention.
• Consult a GP or dermatologist if hair loss is patchy, severe, or associated with scalp changes.

'Mounjaro face' and facial sagging

'Mounjaro face' describes facial changes from rapid fat loss: a gaunt or hollow appearance, skin laxity around the jawline and cheeks, and a 'tired' look. This is a consequence of subcutaneous fat loss rather than a drug effect, skin may not contract as quickly as the fat disappears. A more gradual rate of weight loss can help mitigate this.

Other body composition changes

Rapid weight loss can reduce muscle mass if caloric intake is restricted without adequate protein and resistance exercise. A structured programme combining resistance and cardiovascular training is strongly recommended throughout treatment.

How long do Mounjaro side effects last?

Most patients report mild nausea, reduced appetite, and sometimes light-headedness after the first 2.5 mg injection. These typically subside within 2–3 days. Side effects often resurface at each dose increase and generally resolve within 2–4 weeks at the new dose. If they don't, speak to your prescriber about extending the time at the current dose before increasing further.

After a missed dose:

• If within 4 days (96 hours) of your usual injection day, administer it as soon as you remember.
• If more than 4 days have passed, skip it and resume your next scheduled dose.
• Never take two doses in the same week.

Serious and long-term risks: What the evidence shows

While the majority of people taking Mounjaro experience only mild, manageable side effects, a small number of more serious complications have been identified in clinical trials and post-marketing surveillance. These are rare, but it is important to know what to look out for so you can act quickly if needed.

Acute pancreatitis

Rare (less than 1 in 1,000), but serious. Seek urgent medical help for severe, persistent abdominal pain radiating to the back, especially with nausea, vomiting, or fever. Mounjaro should be stopped immediately and not restarted after a confirmed episode. Those with a personal or family history of pancreatitis should discuss the risk–benefit balance with their prescriber before starting.

Gallbladder problems (Gallstones and Cholecystitis)

Rapid weight loss increases the risk of gallstones regardless of method. Classified as uncommon with Mounjaro. Symptoms include right-sided abdominal pain after fatty meals, nausea, or jaundice. If you experience any of these, they should be reported to your GP promptly.

Kidney and urinary issues

Dehydration from vomiting or diarrhoea can impair kidney function, particularly in those with pre-existing kidney disease. Acute kidney injury has appeared in post-marketing data as a consequence of dehydration, not as a direct drug effect. Maintain adequate hydration and seek help if you experience dark urine, dizziness, or significantly reduced urination.

Thyroid concerns: Animal data, human evidence, and contraindications

Tirzepatide caused thyroid C-cell tumours in rodent studies, but no causal link has been established in humans (as of the most recent MHRA review). Rodents have a higher density of GLP-1 receptors in thyroid C-cells than humans, making direct extrapolation uncertain. Post-marketing surveillance is ongoing.

Eye effects

Emerging data suggest rapid blood sugar improvements may temporarily worsen diabetic retinopathy in some patients — a pattern also seen with other intensive glucose-lowering treatments. This has not been prominently reported in non-diabetic users. Patients with existing diabetic eye disease should maintain regular ophthalmology follow-up.

Mental health and suicidal ideation

A 2024 EMA review concluded that available evidence does not confirm a causal link between GLP-1 medicines and suicidal or self-harm thoughts, though monitoring continues.

Side effects in people using Mounjaro for weight loss (Without Type 2 diabetes)

The side effect profile is broadly similar in non-diabetic users, with some important distinctions:

• Hypoglycaemia is significantly less common, as Mounjaro's insulin-stimulating effect is glucose-dependent, though it can still occur if meals are skipped.
• Muscle loss is a greater concern without the metabolic benefit of improved insulin sensitivity; adequate protein and resistance exercise are essential.
• Weight regain: SURMOUNT-4 data showed participants who stopped tirzepatide regained approximately two-thirds of lost weight within one year.
• Nutritional deficiencies: Reduced caloric intake can cause deficiencies in B12, iron, folate, and vitamin D. Periodic blood tests are advisable.

Mounjaro vs Wegovy side effects

Both Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4 mg) share many side effects as a result of their GLP-1 receptor agonism. The table below outlines the key similarities and differences.

SURMOUNT-5 (2024) suggests Mounjaro produces greater average weight loss than Wegovy, but does not show a clinically meaningful difference in tolerability at comparable titration schedules.

Real-world patient experiences

Clinical trial data only tells part of the story. Here is what patients commonly report in practice, balanced against what the evidence shows.

Positive Experiences

• Marked reduction in appetite and 'food noise'.
• Meaningful weight loss within the first 4–8 weeks.
• Improved energy and mobility once the initial GI adjustment period passes
• Better blood sugar control (for those with T2D).

Commonly reported challenges

• Nausea and fatigue in the days after each injection, especially at lower starting doses.
• Difficulty eating enough protein when appetite suppression is at its strongest.
• Hair thinning around months 3–4, causing anxiety for some.
• Facial changes prompting concern, despite significant improvements in clinical health markers.
• Injection-site discomfort, though most patients adapt quickly.

Clinical trial data from SURMOUNT-1, -2, and -3 showed discontinuation due to adverse events in approximately 4–8% of participants, with GI events as the primary reason. The large majority completed the trials and experienced substantial benefits.

Practical management strategies for Mounjaro side effects

Most Mounjaro side effects are manageable with straightforward adjustments to diet, hydration, and lifestyle. The strategies below are drawn from clinical guidance and real-world patient experience, but if symptoms persist or significantly affect your daily life, always speak to your prescriber.

Dietary advice

• Eat 4–5 smaller meals per day rather than 3 large ones.
• Prioritise protein at every meal (aim for 25–35 g per meal).
• Reduce high-fat, spicy, and heavily processed foods, especially in the early weeks.
• Introduce fibre gradually; prioritise soluble sources (oats, lentils, bananas).
• Eat slowly and stop at the first sign of fullness.

Hydration

• Aim for 1.5–2 litres of fluid daily, prioritising water.
• Use oral rehydration solutions if vomiting or diarrhoea are significant.
• Limit alcohol, which worsens nausea and dehydration.

Over-the-counter remedies

• Nausea: Antihistamine-based antiemetics (e.g., promethazine); ginger tea or capsules for mild symptoms.
• Indigestion / heartburn: Antacids (e.g., Gaviscon, Rennie) or low-dose omeprazole 20 mg (available OTC).
• Constipation: Osmotic laxatives such as macrogol (e.g., Movicol) are first-line.
• Diarrhoea: Loperamide (e.g., Imodium) for acute episodes, only if no blood in stool and you are not chronically unwell.

Lifestyle adjustments

• Avoid strenuous exercise on injection day. Fatigue and nausea are common.
• Keep a symptom diary to identify personal triggers and share patterns with your prescriber.
• Discuss slower titration if side effects are difficult to manage. There is no benefit to rushing dose increases.

When to seek urgent medical help and how to report side effects

Most people taking Mounjaro will not experience anything more serious than manageable gastrointestinal discomfort. However, it is important to know the warning signs that require prompt action, and how to report any suspected side effects to the appropriate authorities.

Call 999 or go to A&E for:

• Severe, persistent abdominal pain (possible pancreatitis).
• Signs of anaphylaxis: swelling of face, lips, tongue, or throat; difficulty breathing; severe rash.
• Serious dehydration: extreme dizziness, very dark urine, confusion, inability to keep fluids down.
• Chest pain or rapid/irregular heartbeat.

Contact Your GP or prescriber promptly for:

• Persistent vomiting or diarrhoea lasting more than 48 hours.
• A lump or swelling in the neck.
• Significant mood changes or thoughts of self-harm.
• Visual changes or eye problems.
• Right-sided abdominal pain (possible gallbladder issue).
• Any side effect significantly affecting daily life.

Reporting via the MHRA Yellow Card scheme

Report suspected side effects, even if you are unsure they are drug-related, at yellowcard.mhra.gov.uk, via the Yellow Card app, or by asking your prescriber to report on your behalf.

Contraindications

Mounjaro must not be used if you have:

• A personal or family history of MTC or MEN 2.
• A known allergy to tirzepatide or any PIL excipients.
• Pregnancy or breastfeeding (effective contraception advised during treatment and for at least one month after the last dose).

Use with caution if you have inflammatory bowel disease, gastroparesis, severe kidney or liver impairment, or a history of pancreatitis. A full medication review with your prescriber is essential before starting.

Final thoughts

Mounjaro is a highly effective treatment, but like any medicine, can cause side effects, the majority of which are temporary, manageable, and improve as your body adjusts to the dose. The serious risks are rare, and knowing what to watch for means you can act quickly if something does not feel right.

At DoktorABC we are happy to advise you if you have any questions about Mounjaro. If you experience a side effect that is not covered here, do not hesitate to report it via the MHRA Yellow Card scheme.

FAQ